Resultats de la cerca - Quanli Gao
- Mostrar 1 - 16 resultats de 16
-
1
-
2
-
3
-
4
-
5
Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines per Ping Wang, Quanli Gao, Zhenhe Suo, Else Munthe, Steinar Solberg, Liwei Ma, Mengyu Wang, N. A. C. Westerdaal, Gunnar Kvalheim, Gustav Gaudernack
Publicat 2013Artigo -
6
RETRACTED ARTICLE: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner per Xiaomin Fu, Xiaoyan Zhu, Fujun Qin, Yong Zhang, Jizhen Lin, Yuechao Ding, Zihe Yang, Yiman Shang, Li Wang, Qinxian Zhang, Quanli Gao
Publicat 2018Artigo -
7
-
8
A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy per Yuanyuan Wang, Tingxuan Gu, Xueli Tian, Wenwen Li, Ran Zhao, Wenqian Yang, Quanli Gao, Tiepeng Li, Jung‐Hyun Shim, Chengjuan Zhang, Kangdong Liu, Mee‐Hyun Lee
Publicat 2021Artigo -
9
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma per Lu Han, Jishuai Zhang, Jian Zhou, Keshu Zhou, Benling Xu, Linlin Li, Baijun Fang, Qingsong Yin, Xinghu Zhu, Hu Zhou, Xudong Wei, Hongchang Su, Bing-Xiang Zhang, Yanan Wang, Bin Xiang, Quanli Gao, Yongping Song
Publicat 2021Artigo -
10
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study per Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Liudi Yang, Rebecca Elstrom, Jane Huang, William Novotny, Vivian Wei, Jun Zhu
Publicat 2019Artigo -
11
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome per Yuying Liu, Yiliang Fang, Xinfeng Chen, Zhenfeng Wang, Xiaoyu Liang, Tianzhen Zhang, Mengyu Liu, Nannan Zhou, Jiadi Lv, Ke Tang, Jing Xie, Yunfeng Gao, Feiran Cheng, Yabo Zhou, Zhen Zhang, Yu Hu, Xiaohui Zhang, Quanli Gao, Yi Zhang, Bo Huang
Publicat 2020Artigo -
12
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study per Wenqun Xing, Lingdi Zhao, Zheng Yan, Baoxing Liu, Xianben Liu, Tiepeng Li, Yong Zhang, Baozhen Ma, Yonghao Yang, Yiman Shang, Xiaomin Fu, Guanghui Liang, Dongfeng Yuan, Jinrong Qu, Xiaofei Chai, He Zhang, Zibing Wang, Hongwei Lin, Liang Liu, Xiubao Ren, Jiangong Zhang, Quanli Gao
Publicat 2021Artigo -
13
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis per Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu
Publicat 2021Artigo -
14
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial per Yan Zheng, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qin, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu, Quanli Gao, Peng Li, Zongfei Wang, Shilei Liu, Jianping Zhu, Haoran Wang, Haibo Ma, Zhenzhen Liu, Fei Zhao, Jun Zhang, He Zhang, Daoyuan Wu, Jinrong Qu, Jie Ma, Peng Zhang, Wenjie Ma, Ming Yan, Yongkui Yu, Qing Li, Jiangong Zhang, Wenqun Xing
Publicat 2024Artigo -
15
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant per Cheng Zhang, Xiaoqi Wang, Rongli Zhang, Fang Liu, Yi Wang, Zhiling Yan, Yongping Song, Ting Yang, Ping Li, Zhen Wang, Yingying Ma, Lei Gao, Yao Liu, Li Gao, Peiyan Kong, Jun Li, Xu Tan, Jiang F. Zhong, Yuqing Chen, Aibin Liang, Jinhua Ren, Zhenyu Li, Jiang Cao, Quanli Gao, Jian Zhou, Ying Gao, Ding Zhang, Fang‐Yi Fan, Mingzhe Han, Robert Peter Gale, Xi Zhang
Publicat 2020Artigo -
16
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label pha... per Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Yuxian Bai, Wei Li, Yiping Zhang, Guanghai Dai, Dong Ma, Jingdong Zhang, Chunmei Bai, Yunchao Huang, Wangjun Liao, Lin Wu, Xi Chen, Yan Yang, Junye Wang, Shoujian Ji, Hui Zhou, Yan Wang, Zhuo Ma, Yanqi Wang, Bo Peng, Jiya Sun, Christoph Mancao
Publicat 2022Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Biology
Cancer research
Immunology
Cancer
Immune system
Immunotherapy
Oncology
Biochemistry
Chemotherapy
Gastroenterology
Genetics
CD8
Cell biology
Clinical endpoint
In vitro
Surgery
Adverse effect
Astrobiology
Cell
Chemistry
Chimeric antigen receptor
Cytotoxic T cell
In vivo
Randomized controlled trial
Receptor
Refractory (planetary science)
T cell
Antibody